Stock Price and Market Performance Overview
As of the latest trading session, Shree Ganesh Biotech India’s share price closed just 1.52% above its 52-week low of ₹0.65, signalling a near-record trough. Despite a modest uptick of 3.08% on the day, the stock remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring a persistent bearish trend.
Comparatively, the stock outperformed its sector by 1.82% on the day, while the broader Sensex index recorded a gain of 0.15%. However, this short-term positive movement follows a prolonged period of decline, with the stock posting negative returns across multiple time frames.
Extended Period of Negative Returns
Examining the stock’s performance over various intervals reveals a consistent downward trajectory. Over the past week, the stock recorded a decline of 4.29%, contrasting with the Sensex’s modest gain of 0.48%. The one-month period shows a reduction of 10.67%, while the three-month span reflects a 15.19% fall, against Sensex gains of 1.36% and 4.98% respectively.
Longer-term figures present a more pronounced picture. The stock’s performance over one year stands at -35.58%, while the Sensex advanced by 7.89%. Year-to-date, the stock mirrors this 35.58% reduction, whereas the Sensex has appreciated by 9.24%. Over three years, the stock has declined by 64.36%, in stark contrast to the Sensex’s 37.07% rise. The five-year performance is particularly notable, with the stock down 85.83% while the Sensex surged 91.71%. Over a decade, the stock has remained flat at 0.00%, whereas the Sensex has increased by 231.15%.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Financial Health and Profitability Metrics
Shree Ganesh Biotech India’s financial data for the nine months ending September 2025 reveals a contraction in net sales to ₹5.16 crores, representing a decline of 44.64% compared to the previous period. Correspondingly, the profit after tax (PAT) recorded a negative ₹0.61 crores, also reflecting a 44.64% reduction.
The company’s ability to convert sales into cash is further illustrated by a debtors turnover ratio of 0.00 times for the half-year period, indicating challenges in receivables management.
Debt Servicing and Return on Equity
Debt servicing capacity appears constrained, with an average EBIT to interest ratio of 0.91, suggesting that earnings before interest and tax are insufficient to comfortably cover interest obligations. This ratio points to a relatively weak buffer for debt repayment.
Return on equity (ROE) averages at 2.62%, signalling limited profitability generated per unit of shareholders’ funds. This figure is modest within the Pharmaceuticals & Biotechnology sector, where higher returns are typically expected given the capital intensity and innovation-driven nature of the industry.
Valuation and Risk Considerations
The stock is currently trading at levels considered risky relative to its historical valuations. Over the past year, while the stock’s return was negative at 35.58%, profits have contracted by approximately 86.6%, highlighting a significant erosion in earnings.
Majority shareholding remains with non-institutional investors, which may influence liquidity and trading dynamics.
Holding Shree Ganesh Biotech India from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Market Context
Shree Ganesh Biotech India’s stock has experienced a prolonged period of subdued performance, with multiple indicators pointing to a challenging environment. The stock’s proximity to its all-time low, combined with negative returns across short, medium, and long-term periods, reflects a difficult market position relative to the broader index and sector peers.
Financial metrics reveal contraction in sales and profitability, alongside limited capacity to service debt and generate returns for shareholders. The stock’s valuation relative to historical norms suggests elevated risk levels, while the shareholder base remains predominantly non-institutional.
These factors collectively illustrate the severity of the current situation faced by Shree Ganesh Biotech India within the Pharmaceuticals & Biotechnology sector.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
